Menu
ncarol.com
  • Home
  • Music
  • Asheville Music
  • Books
  • Manufacturing
  • Health
  • Technology
  • Business
  • Real Estate
ncarol.com

GenesisCare and OncoBeta announce partnership to provide innovative treatment for non-melanoma skin cancer
ncarol.com/10222142

Trending...
  • Oral statement on the situation of Chairman Lee Man-hee in pretrial detention in the Republic of Korea
  • "JACKIE the STRIPPER," Starring Charlotte Kirk and The PUSSYCAT DOLLS' Kimberly Wyatt, Now Streaming on PRIME
  • Infinity Infusion Solutions Launches "Women Leading Infusion Care" Campaign for National Women in Business Month
GenesisCare + OncoBeta announce partnership
Non-invasive therapy for non-melanoma skin cancer is now available at select GenesisCare treatment sites

MUNICH & SYDNEY - ncarol.com -- OncoBeta® GmbH, a commercial stage medical device company specialized in innovative epidermal radioisotope therapies. And GenesisCare, the largest provider of cancer care in Australia, the UK and Spain are excited to announce a partnership to provide an innovative, non-invasive, single-session treatment for non-melanoma skin cancer. OncoBeta and GenesisCare have recently completed recruitment of a phase 4 clinical trial and are now expanding access to suitable skin cancer patients.

Starting in June 2023 GenesisCare will offer the new therapy from their Tugan clinic, at John Flynn Private Hospital Gold Coast. This will be followed shortly after by GenesisCare clinics at Murdoch at St John of God Hospital – Perth, Chermside Medical Complex – Brisbane, Hurstville at Waratah Private Hospital – Sydney, and Cabrini Hospital – Melbourne.

Australia has the highest incidence of non-melanoma skin cancer in the world, with 32% of Australians treated for non-melanoma skin cancer each year. Recent data indicated that 70% of Australians will have at least one non-melanoma skin cancer excised. People with a history of skin cancer have a greatly elevated risk of developing new lesions. Currently used standard of care surgical treatment options can be scarring and disfiguring. OncoBeta's technology will offer a new and effective treatment option to address this large Australian medical burden.

Nicholas H. Vetter, OncoBeta Group CEO, stated "This is a huge step forward for our organization. We are very excited about working together with GenesisCare to bring our technology for treating non-melanoma skin cancer to Australia. GenesisCare is a strong partner we look forward to collaborating with to reach thousands of Australians afflicted with non-melanoma skin cancer."

More on ncarol.com
  • HW Foundation Opens Nominations for Inaugural 50 Under 50 in AI; Deadline Oct. 16
  • Pavillon 30 Years of Addiction Recovery in Western North Carolina, Earns National Accreditation
  • Charlotte Leadership Strategist Rustie Selected to Compete in National "Top Host" Competition
  • ResC4EU Final Event at KOMPOZYT-EXPO 2026 – Building Resilient European Supply Chains
  • Charlotte Leadership Firm Lead Forward™ Participate in 2026 _preneur Conference

"The partnership with GenesisCare is a significant milestone for OncoBeta in Australia" said Shannon D. Brown III, CEO and Managing Director at OncoBeta® GmbH "This will enhance access to precise, individualised treatments for non-melanoma skin cancer patients. The partnership aligns with our company's vision to improve quality of life for non-melanoma skin cancer patients across Australia".

GenesisCare Chief Medical Officer, Dr Marie Burke, stated "We are looking forward to Australian patients having access to OncoBeta's innovative treatment for non-melanoma skin cancers. This fits well into the treatment portfolio offered at GenesisCare sites and represents a promising new option for certain patients with skin cancer that may be suitable for the single-session, non-invasive treatment".

Always talk to your doctor about what treatment options are suitable for you.

Healthcare Professionals can contact GenesisCare or OncoBeta for more information.


About GenesisCare
GenesisCare is a global healthcare company and one of the world's largest integrated oncology organisations. The company's purpose is to design care experiences that get the best possible life outcomes. This is grounded in the belief that care should be focused on the individual, not the condition.

GenesisCare is the world's largest provider of radiotherapy – a vital treatment option for cancer patients – and provides patients with access to diagnostics, medical oncology, surgical oncology, radiotherapy, and novel therapies alongside the ability to participate in the latest clinical trials. With a growing research and trials program numbering more than 150 clinical trials, a contract research organisation, and global innovation programs focused on precision medicine and novel therapies, GenesisCare aims to bring new therapies to more patients in need in a more affordable way.

More on ncarol.com
  • CardsNearby Launches Free Nationwide Directory of Card Shows and Local Card Shops for Collectors
  • American Garden Rose Selections™ Announces 2027 Winners
  • Crossroads4Hope Launches Blood Cancer Resource Hub
  • NIL Club Data Shows Brands Are Looking Beyond Follower Counts in College Sports
  • Georgia's Magical Nights of Lights Bigger and Brighter for 2026

Every year, GenesisCare clinical teams see more than 450,000 people across 350+ locations, including more than 300 locations in the U.S., 40 in Australia, 14 in the UK, and 18 in Spain. Headquartered in Sydney, Australia, the organisation employs more than 5,500 highly trained physicians, healthcare professionals and support staff across Australia, Europe, and the U.S.

For more information visit www.genesiscare.com/au

About OncoBeta® GmbH
OncoBeta®, with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies. Since its foundation, OncoBeta has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting NMSCs. OncoBeta has perfected the customized application and device management system in conformity with all health, safety and environmental protection regulatory standards.

Find out more at www.oncobeta.com

Follow us on social media:
LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
Facebook: https://www.facebook.com/oncobeta/

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control, and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Source: OncoBeta GmbH
Filed Under: Business, Health

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • AI, Real-World Data "RWD" and U.S. Expansion Put Predictive Healthcare in Focus for POMDOCTOR Ltd. (N A S D A Q: POM)
  • $11.18 Million DARPA Award Ignites a Major New Catalyst as FDA, Robotic TMS and Commercialization Milestones Converge for NRx Pharmaceuticals, Inc
  • 2026 Triangle Parade of Homes Features Over 300 Homes
  • "Next Friday" Star Mike Epps Hits Cherokee as KayeDinero Drops "Cherokee"
  • P-Wave Classics to publish Thomas Holcroft's The Adventures of Hugh Trevor in three volumes, beginning 19 January
  • Ad Leverage Sponsors ServiceTitan Pantheon 2026, Supporting Education and Growth in the Home Services Industry
  • Travel Season Turns to the Smokies as KayeDinero Turns Cherokee Into a Song
  • DBF Viewer 2000 v9.32 Adds New Control for Data Export
  • Badanamu Partners With Moonbug Entertainment In Landmark Distribution Deal
  • Cabinet Revolution Expands Affordable Cabinet Options for High Country Homes
  • Nutriband (N A S D A Q: NTRB): Fighting Back Against the Fentanyl Crisis With a New Approach to Safer Transdermal Medicines
  • Oral statement on the situation of Chairman Lee Man-hee in pretrial detention in the Republic of Korea
  • Shuttle Buddy Announces Amazon Partnership to Launch Workforce Express in North Carolina
  • Inlow Upholstery Helps Cleveland County Homeowners Refresh Furniture with Custom Upholstery
  • Birthstones Are Having a 2026 Moment. KayeDinero's "Aquamarine" Began With Her Grandmother
  • Names Are Not Important Asks What Remains When Identity Is Stripped of Labels
  • Most Utah Deaths Never Reach the Medical Examiner. Postmortem Pathology Offers Salt Lake City a Private Autopsy Option
  • Virtually Tour Heritage at South Brunswick's Resort-Style Living - Experience Indoor and Outdoor Amenities at Your Fingertips
  • A Dependable Marks 29 Years of Home Remodeling and General Contracting in the Charlotte Region
  • Living Waters Inc to Host Mental Health Summit
_catLbl0 _catLbl1

Popular on ncarol.com

  • Warrant Activity, AVERSA™ Progress and a Potentially Transformative Fall Take Center Stage: Nutriband Inc. (N A S D A Q: NTRB) - 121
  • Santa Your Way Announces Official 2026 Q4 Holiday Tour: Booking Open For Santa, The 5-star Grinch, And Dual Character Experiences Nationwide - 111
  • FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP) - 108
  • USA Air Management Marks 30 Years of Air Duct Cleaning in NJ Urges Homeowners to Schedule Dryer Vent Cleaning Before Heating Season - 106
  • Gabby Press Earns High Praise From Feathered Quill About the Unregulated Dangers of Second Generation Corporate AI - 103
  • Gary Bernstein Expands Media Leadership Role With Senior Strategic Advisor Appointment To Blacksun Private Equity
  • Growth Story Expands: $54.6M Contract, $30M Revenue Run Rate, 800+ Customers, 50+ Patents & New AI Cybersecurity Products for Cycurion, Inc $CYCU
  • Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
  • Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
  • Heritage at Manalapan Welcomes New Sales Team as Luxury Single-Family Home Community Continues to Grow

Similar on ncarol.com

  • Bruce Paulson Crowned The King of PBNs by the League of Lazy SEOs
  • Guardian Data Opens 42,000-Square-Foot Moonachie Facility, Doubling New Jersey Capacity
  • SecureMaine 2026 is Here -- Thursday October 8th!
  • Pavillon 30 Years of Addiction Recovery in Western North Carolina, Earns National Accreditation
  • Charlotte Leadership Strategist Rustie Selected to Compete in National "Top Host" Competition
  • ResC4EU Final Event at KOMPOZYT-EXPO 2026 – Building Resilient European Supply Chains
  • Charlotte Leadership Firm Lead Forward™ Participate in 2026 _preneur Conference
  • Crossroads4Hope Launches Blood Cancer Resource Hub
  • NIL Club Data Shows Brands Are Looking Beyond Follower Counts in College Sports
  • Harvard Educated Board Certified Endodontist Joins Pearlfection Dentistry
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute